Roche Holding AG (RHHBY) Q3 2024 Sales/Trading Statement Call
Roche Holding AG (RHHBY) Q3 2024 Sales/Trading Statement Call
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024
RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.
Roche comes out against clearing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
Roche Increases Dividend on Higher Sales
Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus lifted sales in the first nine months of the year.
Roche Q3 sales advance by forex-adj 9%, beating market view
Roche on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion).
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Over the last couple of years, one of the biggest stories in the stock market has been around pharmaceutical companies that are thriving due to the proliferation of their weight loss drug treatments. The two firms that most readily come to mind are Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO.
China is 'fighting hard', but mainly in the wrong direction: David Roche
David Roche of Quantum Strategy says the complexity of the issue in China is not being comprehended by the authorities, and discusses what measures he thinks are needed to "get the economy moving".
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Roche CEO: breast cancer pill could be in 10 bln CHF market if trials succeed
Roche's CEO said on Wednesday that the Swiss drugmaker's oral drug candidate for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($11.66 billion) annually if it succeeds in two key trials on early treatment of the disease.
David Roche says misleading 50-basis-point Fed cut will create market instability
David Roche, strategist at Quantum Strategy, says the Federal Reserve's initial jumbo cut gives markets the wrong impression that rates will return to rock bottom.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.
Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
Roche has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical industry's fastest-growing market. Speaking to Bloomberg Television, Schinecker said combination therapy could help treat kidney, liver and heart disease.
